Vivo Capital LLC boosted its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Rating) by 68.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,681,199 shares of the biotechnology company’s stock after acquiring an additional 681,199 shares during the quarter. Astria Therapeutics comprises 2.9% of Vivo Capital LLC’s portfolio, making the […]
Opaleye Management Inc. grew its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Rating) by 96.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 261,703 shares of the biotechnology company’s stock after acquiring an additional 128,203 shares during the period. Astria Therapeutics comprises 1.4% of Opaleye […]
Opaleye Management Inc. increased its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Rating) by 96.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 261,703 shares of the biotechnology company’s stock after acquiring an additional 128,203 shares during the quarter. […]
Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Rating) was the recipient of a large decrease in short interest in April. As of April 15th, there was short interest totalling 573,400 shares, a decrease of 16.1% from the March 31st total of 683,300 shares. Based on an average daily trading volume, of 224,800 shares, the days-to-cover ratio […]
Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Rating) shares crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $12.24 and traded as low as $11.35. Astria Therapeutics shares last traded at $11.73, with a volume of 94,585 shares changing hands. Analysts Set New Price […]